Table 1 Summary of clinical trials in RCC
Trial | Treatment | Control | Year | No. of Patients (treatment v. control) | Primary endpoint | Secondary endpoint | Median FU period (months) |
|---|---|---|---|---|---|---|---|
COMPARZ | Pazopanib | Sunitinib | 2013 | 1110 (557 v. 553) | PFS | OS, safety, QoL | NA |
CheckMate 214 | Nivolumab + Ipilimumab | Sunitinib | 2018 | 1096 (550 v. 546) | OS, ORR, PFS (IMDC Intermediate or poor prognostic risk) | OS, ORR, PFS (overall) | 25.2 |
JAVELIN renal 101 | Axitinib + Avelumab | Sunitinib | 2019 | 886 (442 v. 444) | OS, PFS (PD-L1+) | PFS (overall), ORR, safety | 9.9 |
Keynote 426 | Axitinib + Pembrolizumab | Sunitinib | 2019 | 1062 (432 v. 429) | OS, PFS | ORR | 12.8 |
CLEAR | Lenvatinib + Pembrolizumab | Sunitinib | 2021 | 712 (355 v. 357) | PFS | OS | 26.6 |
CheckMate 9ER | Cabozantinib + Nivolumab | Sunitinib | 2021 | 651 (323 v. 328) | PFS | OS, ORR | 18.1 |